Table 3. Characteristics of HIV-1 positive patients with HBeAg seroclearance or not during chronic B infection.

| **Characteristics** | **Category** | **Overall CBI****(n=23)** | **HBeAg seroclearance****(n=15)** | **HBeAg persistence** **(n=8)** | **P-valuea** |
| --- | --- | --- | --- | --- | --- |
| Age |  | 37.4 (34.5 - 40.7) | 36.8 (34.5 - 41) | 38.7 (33.9 - 40.5) | 0.771 |
| Male sex |  | 23 (100%) | 15 (100%) | 8 (100%) |  |
| HIV risk factor |  |  |  |  | 0.194 |
|  | MSM | 12 (52.2%) | 9 (60%) | 3 (37.5%) |  |
|  | IVDU | 2 (8.7%) | 2 (13.3%) | 0 |  |
|  | Other/Unknown | 9 (39.1%) | 4 (26.7%) | 5 (62.5%) |  |
| Years of HIV infection |  | 3.1 (0.04 - 5) | 2.2 (0.04 - 7.5) | 3.2 (0.64 - 4.9) | 0.871 |
| On DAART |  | 8 (34.8%) | 5 (33.3%) | 3 (37.5%) | 0.842 |
| Years of DAARTb |  | 3.7 (2.3-5.0) | 4.3 (2.6-5.0) | 2.9 (2.3-4.3) | 0.523 |
| Cumulative exposure to 3TC/FTC/TDF before AHB (months) |  | 42 (19 - 64) | 59 (24 - 60) | 23 (3 - 68) | 0.551 |
| Cumulative exposure to 3TC/FTC/TDF after AHB (months) |  | 145 (52 - 169) | 143 (53 - 187) | 145 (52 - 155) | 0.635 |
| Cumulative exposure to FTC/TDF after AHB (months) |  | 139 (34 - 177) | 133 (35 - 199) | 145 (32 - 155) | 0.65 |
| Calendar year of AHB |  | 2003 (2001-2014) | 2008 (2002-2014) | 2003 (2001-2007) | 0.517 |
| Nadir CD4+ cells/µL |  | 270 (181 - 384) | 304 (108 - 420) | 253.5 (211 - 332) | 0.974 |
|  | ≤200 cells/µL | 8 (34.8%) | 6 (40%) | 2 (25%) | 0.657 |
| Anti-HCV |  |  |  |  | 0.311 |
|  | Negative | 20 (87%) | 13 (86.7%) | 7 (87.5%) |  |
|  | Positive | 2 (8.7%) | 2 (13.3%) | 0 (0%) |  |
|  | Unknown | 1 (4.3%) | 0 | 1 (2.5%) |  |
| HIV-RNA copies/mL (available in 17 subjects) |  | 365 (49 - 24000) | 310 (49- 24000) | 523 (120 - 75857) | 0.620 |
|  | < 50 copies/mL | 6 (35.3%) | 5 (45.5%) | 1 (16.7%) | 0.333 |
| CD4+, cells/µL |  | 543 (279 - 646) | 611 (279 - 680) | 485 (363 - 543) | 0.437 |
| CD4% |  | 24.7 (17.3-29.2) | 30.4 (16.4 - 34) | 16.6 (9.6 - 22.4) | 0.143 |
| CD8+, cells/µL |  | 870 (684 - 1352) | 746 (644 - 870) | 1709 (1352 - 2236) | 0.008 |
| CD8% |  | 49.7 (41.2 - 60) | 43.5 (39.2 - 50.6) | 57.2 (54.8 - 60.5) | 0.022 |
| CD4+/CD8+ ratio |  | 0.43 (0.26 - 0.77) | 0.72 (0.4 - 0.95) | 0.28 (0.16 - 0.39) | 0.089 |
| AST levels, U/L c |  | 494 (273 - 1143) | 600 (253 - 1143) | 441 (362.5 - 1328) | 0.948 |
| ALT Levels, U/Ld |  | 1034 (669 - 2747) | 713 (508 - 2747) | 1094 (921 - 2827) | 0.396 |
| Total bilirubin, mg/dL |  | 1.26 (0.7 - 4.8) | 1.26 (0.85 - 5.2) | 1.09 (0.51 - 2.05) | 0.396 |
| HIV-RNA, copies/mL at last visit |  | 49 (49- 49) | 49 (49- 49) | 49 (49-491) | 0.101 |
|  | <50 copies/mL | 18 (78.3%) | 13 (86.7%) | 5 (62.5%) | 0.297 |
| CD4+, cells/µL at last visit |  | 639 (422 - 858) | 757 (602 - 858) | 497 (344.5 - 768) | 0.208 |
| CD4% at last visit |  | 28 (21.9 - 37.5) | 30.1 (26 - 37.6) | 18.9 (12.5 - 27.6) | 0.036 |
| CD8+, cells/µL at last visit |  | 1033 (791 - 1551) | 838 (687 - 1192) | 1458 (822 - 2473) | 0.146 |
| CD8% at last visit |  | 46.5 (37.9 - 51.9) | 41.2 (34.9 - 48.9) | 51.6 (43.6 - 67.9) | 0.129 |
| CD4+/CD8+ ratio at last visit |  | 0.62 (0.48 - 0.95) | 0.77 (0.53 - 1.17) | 0.38 (0.19 - 0.63) | 0.049 |
| ASTlevels, U/L at last visit |  | 26 (23 - 38) | 24 (23 - 26) | 40 (30 - 54) | 0.069 |
| ALTlevels, U/L at last visit |  | 31 (18 - 63) | 25 (18 - 34) | 63.5 (42.5 - 104) | 0.033 |
| Total bilirubin mg/dL at last visit |  | 0.73 (0.42 - 1.29) | 0.73 (0.42 - 0.96) | 0.83 (0.41 - 2.38) | 0.747 |

Characteristics were measured at the date of AHB unless otherwise specified. Results were reported as median [interquartile range (IQR) or frequency (%)].

aBy use of the chi-square/Fisher’s exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables.

bYears of DAART were calculated for patients on treatment at AHB.

cAST normal values <35 U/L; dALT normal values <59 U/L.

Abbreviation: CBI, chronic HBV infection; DAART, dually acting antiretroviral therapy; MSM, men who have sex with men; IVDU, Intravenous drug users.

Table 4. Characteristics of HIV-1 positive patients with HBsAg seroclearance or not during chronic B infection.

| **Characteristics** | **Category** | **Overall CBI****(n=23)** | **Seroclearance of HBsAg****(n=11)** | **HBsAg persistence****(n=12)** | **p-valuea** |
| --- | --- | --- | --- | --- | --- |
| Age |  | 37.4 (34.5 – 40.7) | 37.5 (34.5 – 41) | 37.1 (33.7 – 40.5) | 0.998 |
| Male sex |  | 23 (100%) | 11 (100%) | 12 (100%) |  |
| HIV risk factor |  |  |  |  | 0.079 |
|  | MSM | 12 (52.2%) | 7 (63.6%) | 5 (41.7%) |  |
|  | IVDU | 2 (8.7%) | 2 (18.2%) | 0 (0%) |  |
|  | Other/unknown | 9 (39.1%) | 2 (18.2%) | 7 (58.3%) |  |
| Years of HIV infection |  | 3.1 (0.04 – 5) | 2.2 (0 – 7.5) | 3.2 (0.2 – 4.9) | 0.926 |
| On DAART |  | 8 (34.8%) | 4 (36.4%) | 4 (33.3%) | 0.879 |
| Years of DAARTb |  | 3.7 (2.3-5.0) | 4.9 (3.7-5.0) | 2.7 (2.3-4.3) | 0.315 |
| Cumulative exposure to 3TC/FTC/TDF before AHB (months) |  | 42 (19 - 64) | 59 (42 - 136) | 19 (9 - 46) | 0.194 |
| Cumulative exposure to 3TC/FTC/TDF after AHB (months) |  | 145 (52 - 169) | 122 (48 - 161) | 155 (52 - 196) | 0.532 |
| Cumulative exposure to FTC/TDF after AHB (months) |  | 139 (34 - 177) | 111 (27 - 153) | 155 (35 - 196) | 0.341 |
| Calendar year of AHB |  | 2003 (2001-2014) | 2008 (2002-2015) | 2003 (2000-2007) | 0.156 |
| Nadir CD4+ cells/µL |  | 270 (181 - 384) | 304 (90 - 445) | 254 (185 - 343) | 0.926 |
|  | ≤200 cells/µL | 8 (34.8%) | 4 (36.4%) | 4 (33.3%) | 0.997 |
| Anti-HCV |  |  |  |  | 0.138 |
|  | Negative | 20 (87%) | 9 (81.8%) | 11 (91.7%) |  |
|  | Positive | 2 (8.7%) | 2 (18.2%) | 0  |  |
|  | Unknown | 1 (4.3%) | 0 | 1 (8.3%) |  |
| HIV-RNA copies/mL(available in 17 subjects) |  | 365 (49 - 24000) | 58 (49- 540) | 1748 (135 - 50553) | 0.07 |
|  | <50 copies/mL | 6/17 (35.3%) | 2/10 (20%) | 4/7 (57.1%) | 0.162 |
| CD4+ cells/µL |  | 543 (279 - 646) | 462.5 (165 - 680) | 543 (406 - 611) | 0.949 |
| CD4%  |  | 24.7 (17.3-29.2) | 28.8 (16.4 - 42.5) | 21.4 (11.7 - 30.4) | 0.284 |
| CD8+ cells/µL |  | 870 (684 - 1352) | 684 (608 - 850) | 1352 (890 - 2023) | 0.020 |
| CD8% |  | 49.7 (41.2 - 60) | 45.2 (38 - 51.2) | 54.75 (44.5 - 58.1) | 0.128 |
| CD4+/CD8+ ratio |  | 0.43 (0.26 - 0.77) | 0.62 (0.33 - 1.12) | 0.39 (0.19 - 0.68) | 0.336 |
| ASTc levels U/L |  | 494 (273 - 1143) | 826 (600 - 2368) | 362.5 (206.5 - 488) | 0.043 |
| ALTd levels U/L |  | 1034 (669 - 2747) | 1770 (713 - 2996) | 758.5 (415 - 1094) | 0.118 |
| Total bilirubin, mg/dL |  | 1.26 (0.7 - 4.8) | 1.26 (0.85-5.20) | 1.09 (0.41-2.61) | 0.432 |
| HIV-RNA at last visit |  | 49 (49 - 49) | 49 (49- 49) | 49 (49- 151.5) | 0.838 |
|  | <50 copies/mL | 18 (78.3%) | 9 (81.8%) | 9 (75%) | 0.998 |
| CD4+ cells/µL at last visit |  | 639 (422 - 858) | 757 (602 - 840) | 571 (416 - 1040) | 0.735 |
| CD4% at last visit |  | 28 (21.9 - 37.5) | 29.1 (26 - 36) | 25.2 (15.0 - 44.5) | 0.479 |
| CD8+ cells/µL at last visit |  | 1033 (791 - 1551) | 1163 (687 - 1271) | 839 (798 - 2019) | 0.878 |
| CD8% at last visit |  | 46.5 (37.9 - 51.9) | 46.5 (37.9 - 51.7) | 46.2 (38.1 – 59.0) | 0.758 |
| CD4+/CD8+ at last visit |  | 0.62 (0.48 - 0.95) | 0.69 (0.51 - 0.95) | 0.58 (0.24 - 1.25) | 0.518 |
| AST levels at last visit, U/L |  | 26 (23 - 38) | 25 (23 - 26) | 31.5 (23 - 45.5) | 0.403 |
| ALT levels at last visit, U/L |  | 31 (18 - 63) | 25 (18 - 32) | 56.5 (22.5 - 80.5) | 0.096 |
| Total bilirubin mg/dL at last visit |  | 0.73 (0.42-1.29) | 0.87 (0.43-2.63) | 0.66 (0.40-1.12) | 0.498 |

Characteristics were measured at the date of AHB unless otherwise specified.

Results were reported as median [interquartile range (IQR) or frequency (%)].

aBy use of the chi-square/Fisher’s exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables.

bYears of DAART were calculated for patients on treatment at AHB.

cAST normal values <35 U/L; dALT normal values <59 U/L;

Abbreviation: CBI, chronic HBV infection; DAART, dually acting antiretroviral therapy; MSM, men who have sex with men; IVDU, Intravenous drug users.